Retrospective Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2020; 11(8): 606-613
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.606
Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India
Bharat Vaswani, Sagar Bhagat, Saiprasad Patil, Hanmant Barkate
Bharat Vaswani, Medical Oncology, Yashoda Cancer Institute, Secunderabad 500003, India
Sagar Bhagat, Saiprasad Patil, Hanmant Barkate, Medical Services, Glenmark Pharmaceutical limited, Mumbai 400099, India
Author contributions: Vaswani B and Bhagat S designed the research; Vaswani B performed the research; Bhagat S, Patil S and Barkate H analysed the data; Bhagat S, Patil S and Barkate H wrote the paper.
Institutional review board statement: The study was reviewed and approved by the ethics committee at the St.Theresa's hospital Library.
Informed consent statement: Institutional review board has granted waiver of informed consent based on ethical considerations
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Sagar Bhagat, MD, Doctor, Medical Services, Glenmark Pharmaceutical limited, B D Sawant Road, Andheri East, Mumbai, Maharashtra 400099, India. sagar.bhagat@glenmarkpharma.com
Received: February 17, 2020
Peer-review started: February 17, 2020
First decision: March 28, 2020
Revised: April 9, 2020
Accepted: July 26, 2020
Article in press: July 26, 2020
Published online: August 24, 2020
Core Tip

Core tip: A fixed-dose combination of Netupitant (300 mg) and Palonosetron (0.50 mg) indicated for the prevention of acute and delayed phase of nausea-vomiting in patients on highly and moderately emetogenic chemotherapeutic regimen was recently approved in India. There was no data on the effectiveness of this fixed dose combination in Indian patients in real world setting,the pervious data available was part of regulatory trial conducted in controlled environment, which may not give the real picture of the usage of the molecule in clinical setting. So to look for the effectiveness of the molecule in real world setting this study was conducted among.